← Back
Data updated: Mar 10, 2026
EISAI INC
OncologyNeurologyMetabolic
EISAI INC is a major pharmaceutical company focused on Oncology, Neurology, Metabolic. Key products include LENVIMA.
1990
Since
11
Drugs
-
Trials
12
Approved (2yr)
Key Drugs
Recent Activity
LEQEMBI 2026-01-16
Labeling
LEQEMBI 2025-12-15
Labeling
LEQEMBI 2025-12-15
Labeling
LEQEMBI IQLIK 2025-08-29
LEQEMBI 2025-08-21
Labeling
DAYVIGO 2025-02-19
Labeling
LENVIMA 2025-01-29
Efficacy
LEQEMBI 2025-01-24
Efficacy
LENVIMA 2024-11-20
Labeling
LEQEMBI 2024-11-14
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 52%
2 drugs Phase 3: 2 Phase 2: 11 Phase 1: 17
Neurology 41%
3 drugs Phase 3: 3 Phase 2: 6 Phase 1: 4
Metabolic 5%
0 drugs Phase 2: 2 Phase 1: 2
Respiratory 1%
0 drugs Phase 1: 1
Gastroenterology 1%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Takeda big-pharma
Oncology, Gastroenterology, Neurology, Metabolic
Amgen biotech
Oncology, Metabolic, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Metabolic, Gastroenterology
GSK big-pharma
Respiratory, Oncology, Neurology
Sanofi big-pharma
Metabolic, Oncology, Respiratory